ClinConnect ClinConnect Logo
Search / Trial NCT07008898

Sequence of Midurethral Sling Placement During Robotic Sacrocolpopexy

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jun 5, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Stress Incontinence Pelvic Organ Prolapse Midurethral Sling Sucess Rates Complication Rates Patient Satisfaction

ClinConnect Summary

This clinical trial is studying the best timing for placing a midurethral sling (MUS) during a surgery called robotic sacrocolpopexy. The sling is a small mesh device that helps treat stress urinary incontinence, which is when women leak urine during activities like coughing or laughing. The surgery is designed to fix pelvic organ prolapse, a condition where organs like the bladder or uterus drop from their normal position. The researchers want to find out whether placing the sling before or after lifting and supporting the vagina during surgery is more effective. They will look at how patients feel after the surgery and whether their symptoms improve or worsen.

To participate in this trial, women must be at least 18 years old, able to read and speak English or Spanish, and diagnosed with pelvic organ prolapse along with stress urinary incontinence. They should be planning to have the robotic surgery and need the sling at the same time. The study is not yet recruiting participants, but if you're eligible, you can expect to be part of an important research effort that could improve how these surgeries are done in the future.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • At least 18 years of age
  • Able to speak and read English and Spanish
  • Diagnosis of pelvic organ prolapse stage 2-4
  • Planning to undergo a robotic-assisted sacrocolpopexy
  • Demonstrable SUI (either by CST, with or without prolapse reduction, or UDS) within the year prior to enrollment
  • Planning to undergo concomitant SUI correction with MUS at the time of RSC
  • Exclusion Criteria:
  • Less than 18 years of age
  • Unable to speak and read English or Spanish
  • No diagnosis of SUI (prophylactic slings)
  • History of prior surgery for SUI
  • Bladder capacity \<200 mL or post-void residual (PVR) \>150 mL
  • Current genitourinary fistula or urethral diverticulum

About University Of Alabama At Birmingham

The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.

Locations

Birmingham, Alabama, United States

Patients applied

0 patients applied

Trial Officials

Gabriela E Halder, MD, MPH

Principal Investigator

University of Alabama at Birmingham

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported